January 12, 2024

Dr. Jill Biden  
First Lady of the United States  
The White House  
1600 Pennsylvania Avenue, NW  
Washington, D.C. 20500

Dear Dr. Biden:

We would like to thank you for launching the White House Initiative on Women’s Health Research. While many of us have been working in the trenches for decades to advance the health of women through research, innovation and access, your announcement has sparked broader interest among industry stakeholders to work together to elevate this issue, create public-private partnerships, and finally make the health of women a national priority. We would like to partner with you to ensure that research reaches all patients, especially those marginalized in this country based on sex, race, sexual orientation, income, education, ability status, and geography, among others.

**Overview**

As a professor, you know the importance of creating and maintaining an ecosystem that supports and nourishes research and data that is accurate and translates into increased scientific understanding, innovation, and meaningful impact in people’s lives. Research that is not based on the “real world population” across the United States is less accurate and doesn’t advance the health of all human beings, not just that of women. Finally, research that informs and turns into innovation must reach all patients, especially in underserved populations, to advance the health of women. Therefore, we would like to share the following insights and recommendations to address these priorities for the White House Initiative on Women’s Health Research.

**Women’s Health Research Funding**

With less than 2% private venture funding (when including oncology this rises to 5%) and 11% NIH funding dedicated to women’s health, the first recommendation is for the government to increase research spending on women’s health.¹,² By requiring the NIH institutes to dedicate a minimum percentage of their grant funding toward women’s health research that ensures the total allocation is two to three times higher than 11% and to include at least 50% females in the pre-clinical and clinical trials it funds, we would garner meaningful data to advance further research and the health of women overall. Moreover, an annual report available to the public on this spending by each of the institutes would illuminate and incentivize greater integration of sex-based research and data collection and analysis across the board.

² [https://orwh.od.nih.gov/sites/orwh/files/docs/ORWH_WHC_ExecutiveSummary508.pdf](https://orwh.od.nih.gov/sites/orwh/files/docs/ORWH_WHC_ExecutiveSummary508.pdf)
Recommendations to Improve Research Funding

1. Allocate a minimum percentage goal of annual funding to women’s health research priorities; recommended minimum is to double the current ~11% of total funding within the next two fiscal years and reach ~50% within five fiscal years
2. Within the funded research, mandate inclusion of >50% of self-identified females representing the actual US population in NIH-funded clinical trials
3. Provide an annual report made publicly available on spending by each institute on women’s health research.

Disease Impact Representation in Research

Research that doesn’t include participants who are representative of disease impact also makes the data we use for research, innovation and medical care incomplete and dangerous. With adverse drug events twice as common in women, accurate sex-based data being reported and included on the label is vital to the health and safety of women. Specifically, to address this, women and people of color must be participants in studies in proportion to the disease impact among these populations to ensure accurate data is generated, analyzed and used for drug labeling, further research and development (R&D), and healthcare delivery. These data must be published as such to advance scientific understanding as well. For example, a study on autoimmune disease should have roughly 75-80% women participants since 75-80% of all patients with autoimmune disease are women and it should have significant participation by people of color as African American, Native American and Hispanic women are more susceptible to autoimmune diseases than the general population. Meanwhile a study on cardiovascular disease should have roughly 50% women and 50% men since it is the number one killer of both sexes, but should analyze how therapies impact women and men differently since both the symptoms and expression of heart disease vary by sex. In addition, with the highest percentage of all deaths caused by heart disease when stratified by race being Black (Non-Hispanic) at 22.6%, roughly 22% of heart disease study participants should be of this race.

A final example is in cancer where among all cancers, Black and American Indian/Alaska Native (AIAN) people have higher mortality rates and for major cancers the mortality rate by education level within each race is substantially larger than the Black-White disparities, underscoring how poverty contributes to disparities in health. Diversity in studies is key to gathering accurate data and addressing these disparities. For example, women are disproportionately represented among non-smokers with lung cancer as non-smoking men represent 2-6% of total lung cancer cases among men, but non-smoking women represent

3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275616/
5 https://www.cdc.gov/heartdisease/facts.htm#:~:text=Heart%20disease%20is%20the%20leading,groups%20in%20the%20United%20States.&text=One%20person%20dies%20every%2033,United%20States%20from%20cardiovascular%20disease.&text=About%20695%20000%20people%20in%20the,1%20in%20every%205%20deaths
6 https://www.cdc.gov/heartdisease/facts.htm#:~:text=Heart%20disease%20is%20the%20leading,groups%20in%20the%20United%20States.&text=One%20person%20dies%20every%2033,United%20States%20from%20cardiovascular%20disease.&text=About%20695%20000%20people%20in%20the,1%20in%20every%205%20deaths
approximately 20% of cases among women.\(^8\) For women with breast cancer, there are about 85% higher mortality rates among Black women aged 30–49 years and 136% higher rates among Black women aged 20–29 years.\(^9\) For women with ovarian cancer, where half of all women die within five years of diagnosis—the highest mortality rate of any sex-specific cancer—African-American women experience the poorest 5-year relative survival (36%) while survival for white women is approximately 46%.\(^{10}\) This gap is attributed to earlier age and later stage at diagnosis and disparities across the entire care continuum of ovarian cancer, including diagnosis, treatment, and precision testing.\(^{11}\) Other studies have found race- and sex-based implicit bias as an additional contributing factor in health care delivery and outcomes, which must be addressed in government funded research and when obtaining approval from the Food and Drug Administration (FDA).\(^{12,\ 13}\)

In addition to ensuring diversity and proportionate representation in research that NIH and other federal agencies are funding by mandating half of animal studies include females and by mandating representation by disease impact by sex and ethnicity in clinical trial participation, the government should provide additional funding and guidance to research grant recipients for the explicit purpose of designing clinical trials to align with this inclusive approach that ensures more precise, accurate findings. The same combination of mandates and support should be provided by the FDA in the approval process to enable grant recipients and drug and device sponsors to succeed in generating accurate data that informs medical decision-making for the benefit of all patients. By creating an FDA Center of Excellence in Women’s Health with appropriate staff and training to evaluate innovations, convene companies and patients, and guide them through the approval process, this would accelerate bringing innovations to patients. Many companies are well-meaning but need this additional guidance and incentivization to ensure they run effective, diverse clinical trials.

### Recommendations to Improve Disease Impact Ratio Representation in Research

1. Mandate that women and people of color must be participants in NIH-funded clinical studies in proportion to the disease impact among these populations to ensure accurate data is generated, analyzed and used for drug labeling, future R&D, and healthcare delivery.

2. Mandate 50% of animals in pre-clinical studies be female unless the disease being studied only exists in males.

---

\(^8\) [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827695/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827695/) Of note, the overall rate of lung cancer diagnoses is almost equal among women and men, yet only 15% of NIH lung cancer research is allocated to projects focused specifically on women, according to the WHAM Report. [https://thewhamreport.org/wp-content/uploads/2022/10/TheWHAMReport_Lung_technical.pdf](https://thewhamreport.org/wp-content/uploads/2022/10/TheWHAMReport_Lung_technical.pdf)


\(^11\) [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278570/#:~:text=Black%20patients%20had%2017%E2%80%9318%20survival%20compared%20with%20White%20patients.&text=Potential%20explanations%20include%20earlier%20age,social%2C%20not%20biological%2C%20construct](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278570/#:~:text=Black%20patients%20had%2017%E2%80%9318%20survival%20compared%20with%20White%20patients.&text=Potential%20explanations%20include%20earlier%20age,social%2C%20not%20biological%2C%20construct)

\(^12\) Results of this review suggest that implicit bias against Black, Hispanic/Latino/Latina, and dark-skinned individuals is present among many health care providers of different specialties, levels of training, and levels of experience. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4638275/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4638275/)

3. Provide additional funding and guidance to research grant recipients for the explicit purpose of designing clinical trials to align with this inclusive approach that ensures more precise, accurate findings.

4. Require journal publications to include sex-based data, including data by race, in order to be listed in the NIH Library of publications.

5. Create an FDA Center of Excellence in Women’s Health with appropriate staff and training to evaluate innovations, convene companies and patients, and guide through the approval process to accelerate bringing innovations to patients.

**Access to Care and Innovation**

Yet another concern as you work to reshape the ecosystem for women’s health research is how we bring innovations into care delivery equitably across the United States. According to a recent study, “Despite increased coverage, millions of Americans continued to experience barriers to access to care, which were disproportionately more prevalent among those identifying as Black or Hispanic.”¹⁴ Reaching underserved populations in an accessible, affordable way is key to overcoming current barriers that are more pronounced for people of color, women, low-income and geographically located far from care and/or have few transportation options to access care. These same barriers make participation in clinical trials that can be lifesaving very challenging. Therefore, we ask you to consider the real world lived experience of women, people of color and underserved populations and their access to innovation when building out your research agenda. Research and innovation that does not consider the equitable delivery of care fails to achieve quality and outcomes improvement. We must look closely at the role of cost and affordability in determining access.

Developing effective technologies and therapies for patients is vital, but when this innovation happens, it can exacerbate disparities. For example, bringing rapid testing of biomarkers into the home and to medically underserved populations is essential to improving public health as a nation as well as for individual health. During COVID, innovation in diagnostics exploded with new at-home options that improved access, time-to-treatment, and outcomes. However, the disease impact was still far more severe among Black and Brown populations. This means we still need to ensure the ecosystem fosters innovation but delivers it as equitably as possible. Another example of innovation reaching patients where they live is blood and urine testing at home for everything from Urinary Tract Infections (UTIs) to Sexually Transmitted Infections (STIs) to Diabetes. Advances in research and innovation can help equalize access and overall health even further, especially for women who often have uniquely challenging barriers to traditional healthcare access: childcare responsibilities, shift work, and the juggling of children and jobs and/or limited access to transportation.

Access is also limited by cost. Employed women aged 19-64 spend $15.4 billion (20%) more than employed men in out-of-pocket healthcare costs each year, based on deductibles, coinsurance, and out-of-pocket maximums, worsening existing gender wage disparities.¹⁵ The percentage drops to 18% when

maternity-related services are excluded. This differential often called the “pink tax” means as innovations are developed and enter the marketplace, access can remain a significant challenge.

In addition, insurance coverage plays a role in determining access and affordability of care for most patients. For example, essential screening beyond a mammogram, or what is called “supplemental screening” for breast cancer is covered sporadically despite the life-saving technology that falls into this category being in the marketplace and readily available for years. Approximately 40-50% of all women have dense breasts and mammograms cannot detect tumors in half of all women with dense breasts because the tumor and the tissue are both white in the x-ray image. In fact, 70% of women with breast cancer have dense breasts. MRI, ultrasound and Molecular Breast Imaging are technologies readily available, but insurance often doesn’t cover these technologies and many physicians do not refer patients to them because of lack of coverage. Breast cancer is 99% survivable when caught early but for almost half of all women it is a 50:50 chance of receiving a false negative and only some can afford accessing technology beyond a mammogram that costs approximately $400 each. This technology and many others in women’s health are not quickly and fully reviewed and recommended by the U.S. Preventive Services Task Force (USPSTF). This validation barrier ensures decades of research to advance medical innovation does not reach all patients, unnecessarily causing harm and taking women’s lives.

Overall, access to innovation means access to information, diagnostics, care and treatment that every person deserves to have in order to understand their baseline health and ensure proactive detection of disease. Evidence generation is required to inform medical policy and reimbursement. Therefore, women’s health research must go beyond the laboratory to include strategic planning for reaching patients through implementation research, pilot programs, collaborations with all participants in the ecosystem, and better information gathering, sharing, and reporting. Evidence generation with the goal of acceptance of the evidence and subsequent validation by governing bodies like the FDA and USPSTF ultimately leads to reimbursement. Insurance coverage by both private payers and government payers is a critical dimension of access to innovation as it influences cost and affordability. Women’s health research can be made more accessible by engaging with payers to understand factors influencing coverage and the level of evidence required for reimbursement. As part of the White House’s efforts to advance women’s health research, payers should be consulted to discuss where processes enabling innovation can be supported given how behind we are on women’s health research, e.g. “pilot programs” to measure health and cost improvements following initial validation, a ‘jump the queue’ process for care models and technology specifically dedicated to addressing gaps in women’s health that currently fall outside of medical policy.

Additionally, the government could play a stronger role in this effort by working with innovators as they move through FDA approval and onto Centers for Medicare and Medicaid Services (CMS), TRICARE uniformed services health care program, and Civilian Health and Medical Program of the Department of Veterans Affairs (CHAMPVA) health benefits program’s reimbursement systems by requiring a plan for reaching all patients, especially marginalized populations, to be able to access new innovations. Making these plans public would incentivize intentionality and effectiveness and working with insurers to implement this access is key. Government should provide an annual report to the public on the status of not only newly approved drugs and devices, but of their impact on and plans for reaching patients based

---

16 https://aacrjournals.org/cebp/article/30/10/1913/665633/Breast-Density-Awareness-and-Knowledge-in-a#
on sex- and race-aggregated data and real world evidence of what is needed to enable access. These are valuable steps the government can take to increase access to women’s health innovations.

<table>
<thead>
<tr>
<th>Recommendations to Improve Access to Care and Innovation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Use a multi-dimensional definition of access that includes an understanding of geographic, cost, and psychographic barriers when the government is evaluating access to care.</td>
</tr>
<tr>
<td>2. Require planning for equitable access for all populations when bringing innovation to market via government sponsored programs.</td>
</tr>
<tr>
<td>3. Conduct a review of reimbursement within government and establish parity in what male and female patients pay for care and in the reimbursement rate provided to clinicians.</td>
</tr>
<tr>
<td>4. Expand access to priority innovations in women’s health through a “Breakthrough” process for faster implementation into USPSTF guidelines, which shape the services payers are willing to reimburse.</td>
</tr>
<tr>
<td>5. Work with payers to increase coverage of important innovations that advance the health of women as soon as possible by proactively sharing reports once women’s health innovations are FDA approved with them and the USPSTF, requesting information on their review process and timing for coverage.</td>
</tr>
<tr>
<td>6. Mandate clear communication from the government and designate women’s health pathway for coverage for CMS, TRICARE and VHA.</td>
</tr>
<tr>
<td>7. Require industry to provide meaningful commercialization and adoption guidelines for how innovations will reach diverse patients equitably and make these publicly available.</td>
</tr>
<tr>
<td>8. Produce an annual report on the status of newly approved drugs and devices and their impact on care and outcomes as well as plans for reaching patients based on sex- and race-aggregated data.</td>
</tr>
</tbody>
</table>

Maternal Health and Gynecological Care

A critical aspect of innovation access is maternal health that extends into all aspects of the mental and physical health of women. The Dobbs decision, geographic barriers to care for patients, and the clinician shortage make access to this care particularly challenging. The Dobbs decision did not just accelerate significant restrictions on abortion access and care, but on overall maternal and gynecological care, leading to inadequate clinician training and a shortage of medical professionals throughout the country. As you know, Black maternal mortality rates are nearly three times higher than among white women and Black infants are almost four times as likely to die from complications related to low birthweight. Research and innovation in pre-eclampsia, preterm labor and postpartum hemorrhage remain direly needed for all women to improve outcomes. However, an estimated 2.2 million U.S. women live in “OB-GYN deserts” and 4.7 million more live in areas with limited access. Data now indicates that states with the most restrictive abortion laws also have worse maternal mortality rates and clinicians do not want to work in

---

17 https://www.cdc.gov/nchs/data/hestat/maternal-mortality/2021/maternal-mortality-rates-2021.htm#:~:text=In%202021%2C%20the%20maternal%20mortality,(Figure%201%20and%20Table)
states that are enacting laws restricting the ability to practice medicine in the best interest of female patients.\textsuperscript{20, 21, 22} Many fear infertility restrictions are next.

As the system crumbles with OB-GYN practices shutting down and access to care deteriorating in certain parts of the country, other mental and physical health care needs are often ignored. Therefore, efforts are needed to support equitable care delivery research to develop innovation in maternal health, OB-GYN care, contraceptive care, infertility, mental health and all areas of health, as well as in the delivery of all of the above to patients. We believe that OB-GYN physicians, Women's Health Nurse Practitioners, midwives, and Family Medicine physicians as well as community health workers will play critical, multidisciplinary roles in solving the maternal health crisis and access to care in maternity care deserts. Government support is needed to ensure that we can attract these clinicians to address care gaps.

Moreover, by creating economic incentives and dashboards to measure and convene researchers, clinicians and patients to exchange information and partner in advancing R&D and medical innovations to address these issues, the government can play an important role in closing these gaps. Adding meaningful funding to this effort, removing silos and increasing communications and collaborations that include private sector and NIH, FDA, CMS, AHRQ and HRSA all working together to enable accelerated pathways to bring innovations to patients will ensure thorough, holistic and productive advancements are achieved.

\textbf{Recommendations to Improve Maternal Health and Gynecological Care}

\begin{itemize}
\item 1. Create a grant program to place reproductive health clinicians in “OB-GYN deserts” to ensure access to care, which can include medical school repayment programs and other creative ways to incentivize removing these desserts in care.
\item 2. Include maternal health within the Healthcare Effectiveness Data and Information Set (HEDIS) to measure performance - just as breast cancer screening and immunizations are tracked, so should maternal health care and outcomes.
\item 3. Convene researchers, clinicians and patients from within government (i.e., NIH, FDA, CMS, AHRQ and HRSA) and outside government to exchange information and partner in advancing R&D and medical innovations to address maternal health and contraception gaps through annual symposiums and on-going engagements.
\item 4. Create financial incentives through grant programming or reimbursement systems for organizations that plan to and solve access gaps.
\end{itemize}

In conclusion, there are many challenges and opportunities when it comes to women’s health research and bringing innovation to market in a way that is equitable and meaningful in advancing the health of women. The most pressing areas where access to innovation will have the most impact in population health are from increasing research funding in women’s health, ensuring diverse and representative pre-clinical and clinical participation, closing the gap between FDA approval and inclusion in USPSTF guidelines and

\textsuperscript{20} https://www.axios.com/2022/07/05/maternal-mortality-death-abortion-ban-roe
\textsuperscript{21} https://www.axios.com/2023/04/18/abortion-ban-states-drop-student-residents
coverage by both private and government payers, prioritizing maternal health and reproductive health access, and organizing convenings to advance knowledge and collaborations in women’s health to reach all patients throughout the country.

Thank you for your consideration. This White House Initiative on Women’s Health Research can lead in addressing these women’s health research gaps. We encourage you to make equitable access to innovation the core of this effort in order to fundamentally advance the health of women. If you have questions, please contact Liz Powell at lpowell@G2Gconsulting.com.

Sincerely,

Liz Powell, Esq., MPH
Founder and President
G2G Consulting

Nada Hanafi, MPH
Co-Founder
MedTech Color

Elizabeth Garner, MD, MPH
President
American Medical Women's Association

Mitzi Krockover, MD
Woman Centered, LLC
Owner

Jasmaine McClain, PhD
Executive Director, Health Equity Alliance
The Health Management Academy

Valerie B. Palmieri
CEO/Founder
Momentum Consulting

Tomeka Roberts, MD
OBGYN

Madeleine Livingston, MBA
Director of Strategic Partnerships
Thirty Madison

Linda Goler Blount, MPH
President
Black Women’s Health Imperative

Grace Galvin, MPH
Director of Clinical Innovation
Maven Clinic

Saralyn Mark, MD
Founder/President
iGIANT®

Ifeoma Udoh, PhD
EVP: Policy Advocacy and Science
Black Women’s Health Imperative

Jessica Foley, PhD
Chief Scientific Officer
Focused Ultrasound Foundation

Lydia Pace
Associate Professor of Medicine, Brigham and Women’s Hospital
Connors Center for Women’s Health and Gender Biology

Joined by:

Hadine Joffe, MD MSc
Executive Director, Connors Center for Women's Health; Interim Chair, Department of Psychiatry Harvard Medical School/Brigham and Women's Hospital

Lydia Pace
Associate Professor of Medicine, Brigham and Women’s Hospital
Connors Center for Women’s Health and Gender Biology
Komkwuan Paruchabutr DNP, FNP-BC, WHNP-BC, CNM, FACNM
President, The National Association of Nurse Practitioners in Women's Health

Yolanda Lawson MD
President
National Medical Association

Bethany Corbin, JD, LLM
CEO
FemInnovation

Primavera A Spagnolo, MD, PhD
Scientific Director/Connors Center for Women's Health and Gender Biology
Brigham and Women's Hospital/ Harvard Medical School
Amanda Goltz, MPA
US Lead, Healthcare Startups
Amazon
Amanda Goltz, MPA
US Lead, Healthcare Startups
Amazon

Beth Battaglino, RN
CEO
HealthyWomen

Jennifer Garrison, PhD
Professor
Buck Institute for Research on Aging

Laurie Ambrose
President & CEO
GO2 for Lung Cancer

Fayez Safadi, PhD
Director, Center for Medical Innovation
Northeast Ohio Medical University (NEOMED)

Robin Marty
Executive Director
West Alabama Women's Center

Lebone C. Moses
CEO
Chisara Ventures Inc. and GIV Capital Fund

Christine O'Brien, PhD
Assistant Professor of Biomedical Engineering
Washington University in St. Louis

Leon McDougle, MD, MPH
Associate Dean for Diversity and Inclusion, Chief Diversity Officer, The Ohio State University College of Medicine, The OSU Wexner Medical Center

Ariela Marshall, MD
Associate Professor of Medicine
University of Minnesota and AMWA

Primavera A. Spagnolo, MD, PhD
Scientific Director/Connors Center for Women's Health and Gender Biology; Brigham and Women’s Hospital/ Harvard Medical School

Stasia Obremskey
Managing Director
RH Capital

Allison Grant
Head of Growth
Origin

Kyla McMillion
Woman Centered
Associate

Michelle Wu
Medical Device Consultant, Women’s Health Advocate
Wu Consulting, LLC

Mary Noel
Director of Business Development
Thirty Madison

Jessica Bell van der Wal
CEO
Frame Fertility
Crystal Pirtle Tyler, PhD, MPH  
Chief Health Officer  
Rhia Ventures

Ebony Wrenn, Ed.D.  
Director  
Mom Congress

Oriana Papin-Zoghbi  
CEO  
AOA Dx

Tanisha Hammill, PhD, MPH, MA  
Chief Scientist  
US Air Force Surgeon General’s Office

Andrea Ippolito, M.Eng.  
CEO and Founder  
SimpliFed

Melissa Sherman, PhD  
CEO  
MOBILion Systems Inc.

Vanathi Gopalakrishnan, PhD  
Associate Professor  
University of Pittsburgh School of Medicine

Sylvia Beaulieu  
Chair - Boston Chapter  
Women In Bio

Lynette Kozuma  
Executive Director  
MedtechWOMEN

Millicent Gorham, PhD(Hon), MBA, FAAN  
CEO  
Alliance for Women's Health and Prevention

Neil Parikh, MD MBA  
Chief Medical Officer  
Thirty Madison

Joy Rios, MBA  
 Founder  
HIT Like a Girl Pod

Ediuska Laurens Dr.Eng, M.S.  
Medical Device RA/QA, Product Development Expert  
Genius Shield

Amanda Pinheiro, MS  
PhD Candidate  
Boston University

Ikram Guerd  
VP of Global Marketing - Managing Director US  
Aspivix

Millicent Gorham, PhD(Hon), MBA, FAAN  
CEO  
Alliance for Women's Health and Prevention

Hali Jones PT, DPT  
Clinical Team Lead  
ViFive

Carol Johnson, BCPA (Board certified patient advocate)  
Founder & CEO  
Uterinekind

Trish Hutchison, MD  
CEO  
The Period Education Project

Ingrid Villarreal  
MSc Candidate for Applied Digital Health, The University of Oxford UK  
Board Member, Kendra Scott Women's Entrepreneurship Leadership Institute (KSWELI)

Jodi Neuhauser, MBA  
Founder & CEO  
In Women's Health

Miller Morris, M.A., M.P.H  
Founder and CEO  
Comma

Dr. Jennifer Hintzsche PhD  
CEO & Founder  
PherDal Fertility Science Inc.
Sheila Shah  
Managing Director  
LEK Consulting

Eydis Lima, MSc  
Founder & CEO  
Curiva

Lisa M. Halvorson, MD  
Senior Medical Director  
US Medical Affairs-Women's Health Care,  
Bayer Pharmaceuticals

Carrie M. Kuehn, MA, MPH, DLP, RAC  
Principal Consultant & Founder  
Evergreen Strategic Consulting, LLC

Derek Hillstrom  
VP of Engineering  
Bone Health Technologies

Marisa Cayer RN  
Clinical consultant  
BD

Monica VanBuskirk, MBA  
Managing Director  
MEAPTA Inc.

Lee Spraggon, PhD  
Founder and Chief Technology Officer  
Femmeloop

Lynn M Banaszak  
President  
The Caileigh Lynn McDowell Foundation

Meghan Doyle  
CEO & Co-Founder  
Partum Health

Tawny Hammett, M.Sc.  
Chief Revenue Officer  
Paloma Health

Joanna Flores, MA  
Operations  
Celeste

Joia Crear Perry, MD  
Founder & President  
National Birth Equity Collaborative

Bilikis Oladimeji MD, MMCi  
Physician  
Self-employed

Kristen Stants, MILR  
Chief People Officer  
FogPharma

Madelyn Knowles, MPH  
Co-Founder  
Femtech University Network

Elizabeth Cherot, MD, MBA  
President and CEO  
March of Dimes Inc.

Sai Pranathi Sana, MHA  
Senior Associate, Market Access  
Avalere Health

Sansskriti Thakur  
Chairwoman  
Tower Collective

Tejal Patel, MS  
Senior Program Associate  
Rhia Ventures

Sejal Jain  
Senior Product Manager  
Thirty Madison

Mara Bolis, MBA  
Fellow  
Harvard

Jeanette Numbers,  
CEO + Founder  
Nova Design
Sunaina Kavi, BME, MBA
Founder
Teaspoon Health

Kathleen Keefe
Owner/President
Activities to Go Inc.

Lizzie Murdoch, MBA/MPH
Director Clinical Research
Thirty Madison

Karen Poirier
Founder and Inventor
Embrago (em-BRA-go)

Danielle Neri
VP of Engineering
Parallel Learning

Annie Lewis-O'Connor NP, PhD, MPH, FAAN
Director - C.A.R.E Clinic & Research & Innovation
Brigham and Women's Hospital

Amanda DiTroli
Growth & Operations Lead
Health Tech Nerds

Amanda DePalma
SVP of Corporate and Regional Marketing
Siemens Healthineers

Nandini Kanthi
CEO
Sensible

Nadine Peever
Market Access Director
Innsena

Anish Sebastian
CEO
Babyscripts

Dustin Wuest
VP Data & Analytics
InfoWorks TN

Dr. Tlaleng Mofokeng, MD
Distinguished Lecturer, Center for Global Health Policy & Politics, Georgetown University

Michelle Oyen, PhD
Director, Center for Women's Health Engineering
Washington University in St. Louis

Sara Eyangoh, PhD, HDR
Scientific Director
Pasteur Centre in Cameroon/PASTEUR NETWORK

Cara Tannenbaum MD
Physician
University of Montreal

Indyra Oropeza Aguilar
Founder & President
Con L de Leucemia

Maite Malet
Head of Corp. Development & Investments at Asabys Partners, IEF

Sarah Nicholson
SVP Marketing
Babyscripts

Dr. Anita Gupta, DO, MPP, PharmD, FASA
CEO
Strata Group, Inc.

Valerie Montgomery Rice
President and CEO
Morehouse School of Medicine

Zainab Samad, MBBS, MHS
Professor and Chair, Department of Medicine
Aga Khan University

Lillian Mworeko
Executive Director
International Community of Women Living with HIV in Eastern Africa (ICWEA)
Alemseged Abdiessa, PhD
Physician
Armauer Hansen Research Institute

Ena Kadribasic
Growth Marketer
Thirty Madison

Glenda Ernst, PhD
Head of Translational Research Unit
British Hospital

Alexa Morse, MPH, MBA
Health Strategy Manager
Accenture

Missy Lavender, MBA
CEO
Renalis Health

Lena Rice
Senior Director
The Health Management Academy & The Matriarchy

Katie Loshak
Senior Product Manager
Thirty Madison

Madeline Darcy
Managing Partner
Kaya Ventures

Ana Mocumbi, MD, PhD
Associate Professor
Universidade Eduardo Mondlane

Irene Kuetche Djembissi, PhD
Associate Professor
University of Yaounde 1

Allison Watkins
Founder/CEO
Watkins-Conti Products, Inc.

Laura Holsen, PhD
Associate Professor of Psychiatry
Brigham and Women's Hospital/Harvard Medical School

Rachel Braun Scherl, MBA
Managing Partner
SPARK Solutions for Growth

Kathryn Rexrode, MD, MPH
Chief, Division of Women's Health, Dept of Medicine;
Professor, Harvard Medical School Brigham and
Women's Hospital

Joy Burkhard, MBA
Executive Director
Policy Center for Maternal Mental Health

Deborah Bartz, MD, MPH
Associate Physician/Associate Professor
Brigham and Women's Hospital/Harvard Medical School

Sabrina Johnson
CEO
Daré Bioscience

Nyasha Phanisa Sithole
Co-Founder
DAWA

Simal Ozen Irmak, PhD, MPH, PMH-C
CEO & Co-Founder
Tibi Health Inc.

Peter Pacult, MBA
CEO/Co-Founder
Avana Health

Cephas Adjei Mensah
Director, Ministry of
Environment, Science, Technology & Innovation

Kihara Anne Beatrice, MMED (OB-GYN)
President
International Federation of Obstetricians and Gynaecologists

Eleanor Nwadinobi, MD
President
Medical Women's International Association
Khadija Yahya Malima, PhD  
Physician, Muhimbili University of Health and 
Allied Sciences (MUHAS)

Mariam Jashi MD, MPH, MPA  
Secretary General 
Medical Women's International Association

Jayati Verma  
Former VP of Finance 
Wharton FemTech Club

Kate Dean  
Operations Manager 
Nema Health

Michelle Korte, MPH  
Associate 
Camber Collective

Maya Goldstein  
Director of Research 
Policy Cures Research

Rachel Bartholomew  
CEO 
Hyivy Health

Christopher Doyle MD  
Resident Physician 
Dartmouth Health

Sandra Butler, MPH  
Director, Design Impact 
Mass General Brigham

Eboni Boyd  
CEO 
Museum Advocate

Naseem Sayani, MBA  
General Partner 
Emmeline Ventures

Katherine Kirsch  
Founding Member 
AsteriskDAO

Jim St Clair  
CEO 
MyLigo

Haley Mendez  
Student 
Chicago Booth

Kate Wheeldon, CPA  
Healthcare Leader 
Humana

Lesley Solomon, MBA  
Venture Chair 
Redesign Health

Maya Hardigan  
Founder & CEO 
Mae

Jayne Morgan, MD  
Cardiologist and Executive Director of Health and 
Community Education 
Piedmont Healthcare, Inc.

Andrea Ippolito  
CEO 
SimpliFed

Danika Mills, MSW, LCSW, MPS, CCM, LCAT  
Founder 
Mission Catalyst Consulting LLC

Jordan DeTar  
MBA Candidate 
Columbia Business School

Catherine Unruh, MS  
VP of Research and Development 
KOKO Medical Inc.

Corey Jackson, MS  
Nutrition, strength, nutrition, and hormone 
specialist; Co-Founder and CEO 
FindingSally.ai
Elizabeth Parker Powell, MA, MBA  
Retired; former Chair of Board and President  
DMT

Lauren Orlick  
Co-Founder  
HeartSnug

Sara de Zarraga  
CEO & Co-Founder  
Flare

Quan Zhang  
Chief Financial Officer  
Thirty Madison

Tarul Kode, PharMD  
Executive Leader, Founding Principal  
Ellipsis Healthcare Leadership

Santosh Pandipati, MD, FACOG  
Chief Health Officer, Co-Founder  
e-Lōvu Health

Gillian Wu  
Community Manager  
Health Tech Nerds

Sharon Peterson  
Executive Director  
Montana BioScience Alliance

Anu Sharma  
Founder & CEO  
Millie

Tiffany Aquino, MPH  
Head of Product  
Milk Stork

Christopher McGinty  
Executive Director  
AmericaView

Lori Chmura BSN  
CEO  
Nyra Medical

Jill R. Dietz, MD, MHCM, FACS  
Chief Medical Officer  
CyductDiagnostics

Kristine Brauer, MSN, AG-ACNP, CRNP  
Geriatric CRNP  
Compassus

Nawal Nour  
Chair, Department of Obstetrics and Gynecology  
Brigham and Women’s Hospital

Barbara Callahan, RN  
Medical Sales  
Stratus Neuro

Lalitha Rudraiah, MD  
Physician  
Henry Ford Health

Charu Singhal  
CEO, Co-Founder  
Etta.io

Kathleen Keefe  
Owner / President  
Activities To Go Inc.

Noel Pugh, PhD, JD, MHA  
CEO  
e-Lovu Health

Teresa Derr, MDiv, MSW, LCSW  
Clinician; Advocate Leader  
Yale New Haven Psychiatric Hospital; Ovarian Cancer Research Alliance

Catherine V. Mott  
Managing Partner, Founder  
BlueTree VC Fund/BlueTree Capital Group

Curtis A. Bagne, PhD  
President  
DataSpeaks

Rachel Braun Scherl, MBA  
Managing Partner  
SPARK Solutions for Growth
Elke Lipka, PhD, MBA
CEO
TSRL

Nancy Schoenbrunner, PhD
CEO
AmplifiDx Inc.

Jill Angelo
Founder and CEO
Gennev

Martha Nolan, J.D.
Senior Policy Advisor
HealthyWomen

Kaitlin Mann
Client Relationship Management
Cambridge Associates

Jyoti Gupta, PhD
President & CEO
Women's Health and X-Ray at GE HealthCare

Andrea Linna, JD
Partner
Wilson Sonsini Goodrich & Rosati

Gabriella Palmeri
Head of Partnerships
Healthvana

Dr. Paulina Cecula, MD
Physician
Dama Health

Elena Rueda, MSc
Co-Founder & CEO
Dama Health

Simone Theiss
Program Manager
Tech4Eva

Tawny Hammett, M.Sc.
Chief Revenue Officer
Paloma Health

Caron Trumbo
VP Operations
VA Bio

Zainab Abbas
CEO
SciTech2U

Brittany Barreto, PhD
CEO
FemHealth Insights
Representative Shelia Stubbs
Wisconsin legislature

Audrey D. Sheppard
President
Audrey Sheppard Women's Health Consulting

Prativa Joshi, MBA
Investor
Highmark Ventures

Leena Mittal, MD
Associate Vice Chair for Diversity Equity and Inclusion
Brigham and Women's Hospital

Jack Fraser
Managing Partner
Seamark Capital LP

Karen Mulhauser
President
Mulhauser and Associates

Bishakha Mona
Associate Advisor
Science Philanthropy Alliance

Oriana Papin Zoghbi
CEO
AOA Dx

Kerstin Recker
Co-Founder
Peli Health
Monica Cepak, MBA  
CEO  
Wisp

Pearl D. Cruz  
Founder  
Pearl Consulting

Yimdiuska Magan  
Physician  
Kaiser Permanente Santa Rosa

Bob Johnson  
COO  
Uterinekind, Inc.

Elizabeth Lee, B.Sc., R.N.  
Founder & CEO  
Executive Fertility Consultants

Martha Lawrence  
CEO  
AccendoWave

Dr. Pinkey Patel, PharmD  
CEO/Founder  
Myri Health

Sara T. Brand, PhD  
Founding General Partner  
True Wealth Ventures

Emily Lewis  
Artificial Intelligence and Innovation Lead  
UCB Biopharma

Lindsey Williams,  
CEO  
MyUTI

Becca Williams,  
Founder and CEO  
Menopausey

Kim Hart  
Co-Founder  
MiDOViA

Maryon Stewart, BEM  
CEO  
Femmar Health

Brittany Busse, MD  
President, Chief Medical Officer  
ViTel Health

Kathleen Wisemandle, MS  
Founder  
Aspire to Grow

Sarita Parikh, MSPT  
Founder  
Glow + Gather, Mind, Body & Play Therapies

Guillaume Cohen Skalli  
CEO  
Paloma Health

Dr. Lola Omishore, DPT, PT, OCS, ATC  
Doctor of physical therapy  
TheraMotive

Pita Navarro  
Chief Science Officer, Co-Founder  
Evvy

Heather Underwood, PhD  
Executive, Entrepreneur

Susan Solinsky  
Co-Founder  
Ellipsis Health

Sarah O'Leary  
CEO  
Willow Innovations, Inc.

Elizabeth Prenger  
Co-Founder / CEO  
FemHealth Founders and Fierce Foundry

Felicia "Fee" Sandoval  
Founder & CEO  
Femmeloop
Shallan Ramsey  
CEO, Founder  
MaskIT®

Gabby Pavelko, DACM  
Chief of Staff  
Rootless

Mamta Elias  
Head of Product Strategy  
Caire Health

Somna Pati  
Head of Commercial Growth & Strategy  
Rosy Wellness/South Asian Reproductive Sexual Wellness Association

Miller Morris, MA, MPH  
Founder & CEO  
Comma

Lauren Ross  
VP Finance & Operations  
Shepherd Health, Inc.

Nirshila Chand  
Co-Founder  
Deiya Inc.

Natalia Fields, RN  
CEO  
Cupid Baby

Vanessa Jupe  
CEO  
Women's Health Company

David Jupe  
Flight Attendant  
American Airlines

Dr. Abigail Bales, PT, DPT, CSCS  
Owner  
Reform Physical Therapy

Bayo Curry-Winchell, MD, MS  
Physician/Health Equity Advocate/Founder  
Beyond Clinical Walls

Tracy MacNeal, MBA  
President & CEO  
Materna Medical

Christina Isacson, PhD  
Partner  
Lightstone Ventures

Tracey Sullivan-Victor  
Owner, Independent Talent Acquisition Consultant  
TSV Consulting LLC

Emily Kraus, MD  
Sports Medicine Physician; Female Athlete Researcher  
Stanford University

Julie Yip  
Co-Founder & Engineer  
Ananya Health

Ann Badillo  
Limited Partner  
Portfolia

Nara Lee, JD  
Founder & CEO  
Doveras Fertility

Donna Higgins  
CEO  
The Higgins Group

Kristin Markell, MD  
CEO  
Kristin Markell MD PLLC

Jessica Bell van der Wal  
CEO & Co-Founder  
Frame Fertility

Paula Soteropoulos, MS Sc  
Venture Partner / Chairman of the Board  
5AM Ventures / Ensoma
Ann Garnier  
Co-Founder and CEO  
Lisa Health

Shehnaaz Suliman, MD  
CEO  
ReCode

Neil P. Ray, MD  
CEO & Founder  
Raydiant Oximetry, Inc.

Mackenzie Sharp, MPH  
MPH Candidate  
USC Keck School of Medicine

Sandra Dunn, PhD  
Physician  
Phoenix Molecular Designs

Anna Zornosa-Heymann, MA  
Investor/Advisor  
Self-employed

Amy Millman  
Managing Partner  
StageNext LLC

Gita Vellanki  
Founder  
Neeshi

Nimisha Gandhi, MS, CPM  
Principal Consultant  
ANZZ LLC

Mayra Hurtado  
CEO  
Prelude Health Pte Ltd

Melody Roberts  
CEO  
Liv Labs

Danielle Ralic  
CEO  
Ancora.ai

Stephanie Schull, PhD  
CEO  
Kegelbell

Katelyn Marini  
Managing Director, Women’s Health  
The Bowdoin Group

Sabrina Badir  
Physician  
Pregnolia

Andrea Ippolito, M.S. M.Eng.  
CEO  
SimpliFed

Curtis A. Bagne, PhD  
President  
DataSpeaks, Inc.

Parul Parul  
Chief Enabler  
Athena FundX

Jill Angelo  
Founder and CEO  
Gennev

Emily Man, MS  
CEO  
Venova Technologies

Meg Wirth, MPA  
President  
Maternova

Missy Lavender, MD  
CEO  
Renalis Health

Elizabeth Bailey  
Managing Director  
RH Capital

Lindsey Calcutt, PhD  
CEO  
Incora Health
Bruno Van Tuykom  
CEO and Co-Founder  
Twentyeight Health

Nicole Sandford  
CEO  
Aspira Women’s Health

Colette D. Ellis, MPA  
Founder  
Libbie Health

Dr. Kristen Liesch, PhD  
Co-CEO  
Tidal Equality, Inc.

Kathryn Rexrode, MD, MPH  
Chief, Division of Women's Health, BWH;  
Professor of Medicine, HMS, Brigham and Women's Hospital; Harvard Medical School

Melanie Strong  
Founder and Managing Partner  
Next Ventures

Zaakirah N. Muhammad  
CEO  
Sanicle

Hannah Mamuszka, MS  
CEO  
Alva10

Karen Howlett  
CFO  
Joylux Inc.

Gina Ford, PhD, MBA  
Executive Director  
Women In Bio (WIB)

Betsy Powell, MA, MBA  
Former Chair of the Board, DMT  
Retired

Sabrina Johnson  
CEO  
Daré Bioscience

Eydis Lima, MSc  
Founder & CEO  
Curiva

Callie Estreicher, MBA  
Tower Capital

Karla Loken, DO  
Chief Medical Officer  
FEMSelect.com

Matthias Kleinz, DVM, PhD  
Executive Vice President  
UPMC Enterprises

Lynsey Chediak, MSc  
Associate Director  
Medicines360

Katie Collins  
Vice President  
G2G Consulting

Barbara J. Barry  
Sales/HR  
Hudson's Barbeque

Sarah Gorton  
Educator  
Cleveland Schools

Kelly Carty  
Founder  
MedTech Strategy Advisors, LLC

Michael P. Keefe  
Sales Director  
Consultant

Margaret Malone  
Principal  
Flare Capital Partners